Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Quest Diagnostics Inc (DGX)
Price$236.59Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | $7.15B | $7.38B | $7.39B | $7.26B | $7.46B | $7.25B | $6.70B |
| Gross profit | $3.67B | $3.24B | $3.05B | $3.43B | $4.21B | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | $2.82B | $3.02B | $3.03B | $3.05B | $3.13B | $2.99B | $2.74B |
| Gross margin | 33.21% | 32.86% | 33.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 36.25% | 40.19% | 37.85% | 37.63% | 39.46% | 40.88% | 40.98% | 42.03% | 42.03% | 41.29% | 40.79% |
| Operating expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | $5.67B | $6.18B | $6.41B | $5.98B | $6.10B | $6.03B | $5.61B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983.0M | $1.48B | $1.20B | $987.0M | $1.28B | $1.36B | $1.22B | $1.09B |
| Operating margin | 14.10% | 13.63% | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.74% | 17.70% | 18.67% | 13.22% | 20.64% | 16.27% | 13.35% | 17.68% | 18.23% | 16.86% | 16.28% |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B | $1.76B | $1.49B | $1.27B | $1.54B | $1.62B | $1.49B | $1.33B |
| EBITDA margin | 19.27% | 18.63% | 18.39% | 18.87% | 25.85% | 24.71% | 20.19% | 18.72% | 19.39% | 21.15% | 22.73% | 17.44% | 24.60% | 20.15% | 17.15% | 21.18% | 21.67% | 20.51% | 19.82% |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B | $1.43B | $858.0M | $736.0M | $772.0M | $645.0M | $709.0M | $556.0M | $849.0M | $556.0M | $471.0M | $720.9M | $729.1M | $581.5M | $339.9M |
| Net profit margin | 8.99% | 8.82% | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.43% | 8.94% | 9.46% | 7.48% | 11.88% | 7.53% | 6.37% | 9.93% | 9.78% | 8.02% | 5.07% |
| Basic EPSper basic share | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | $5.58 | $3.49 | $2.95 | $4.08 | $3.91 | $2.99 | $1.76 |
| Diluted EPSper diluted share | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | $5.54 | $3.46 | $2.92 | $4.05 | $3.87 | $2.96 | $1.74 |
Owners
Reported shareholders
8.43%of listed shares
BlackRock, Inc.9.28M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.43%9.28M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.58%7.23M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.57%6.13M shares |
STATE STREET CORP | 5.02%5.52M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.95%5.44M shares |
Boston Partners | 4.31%4.74M shares |
JPMORGAN CHASE & CO | 3.20%3.52M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.85%3.14M shares |
MORGAN STANLEY | 2.24%2.46M shares |
EdgePoint Investment Group Inc. | 2.04%2.25M shares |
DIMENSIONAL FUND ADVISORS LP | 1.81%1.99M shares |
BANK OF AMERICA CORP /DE/ | 1.76%1.94M shares |
Grantham, Mayo, Van Otterloo & Co. LLC | 1.72%1.89M shares |
WELLS FARGO & COMPANY/MN | 1.59%1.75M shares |
Davis Selected Advisers | 1.41%1.56M shares |
VICTORY CAPITAL MANAGEMENT INC | 1.41%1.55M shares |
NORGES BANK | 1.28%1.41M shares |
FMR LLC | 1.27%1.4M shares |
Invesco Ltd. | 1.25%1.38M shares |
NORTHERN TRUST CORP | 1.02%1.13M shares |
Percentages use 110M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 4, 2026Form 4 · 10b5-1 | KUPPUSAMY KARTHIKSVP, Clinical Solutions | SellCommon Stock | 8.1K | $200.00 | $1.63M | 13.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Davis J. E.CEO and President | SellCommon Stock | 10.0K | $194.14 | $1.94M | 132.4K |
| Mar 5, 2026Form 4 · 10b5-1 | Doherty Catherine T.EVP, Regional Businesses | SellCommon Stock | 5.6K | $206.21 | $1.15M | 67.1K |
| Mar 5, 2026Form 4 · 10b5-1 | PREVOZNIK MICHAEL ESVP & General Counsel | SellCommon Stock | 3.9K | $206.21 | $799.7K | 37.6K |
| Mar 5, 2026Form 4 · 10b5-1 | Plewman PatrickSVP for Diagnostic Services | SellCommon Stock | 2.9K | $206.21 | $588.7K | 15.2K |